A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

Cancer Research

Volumn 64, Issue 17, 2004, Pages 5913-5919

  Chen, Lei L ^a   Trent, Jonathan C ^a   Wu, Elsie F ^a   Fuller, Gregory N ^a   Ramdas, Latha ^a   Zhang, Wei ^a   Raymond, Austin K ^a   Prieto, Victor G ^a   Oyedeji, Caroline O ^a   Hunt, Kelly K ^a   Pollock, Raphael E ^a   Feig, Barry W ^a   Hayes, Kimberly J ^a   Choi, Haesun ^a   Macapinlac, Homer A ^a   Hittelman, Walter ^a   Velasco, Marco A ^b   Patel, Shreyaskumar ^a   Burgess, Michael A ^a   Benjamin, Robert S ^a   Frazier, Marsha L ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Vel Lab Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; COMPLEMENTARY DNA; GENOMIC DNA; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR;

ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; DISEASE COURSE; DRUG TARGETING; ENZYME INHIBITION; EXON; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GENE MUTATION; HUMAN; HUMAN CELL; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ALLELES; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CLINICAL TRIALS, PHASE III; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EXONS; GASTROINTESTINAL NEOPLASMS; HUMANS; MUTATION, MISSENSE; PIPERAZINES; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; STROMAL CELLS;

EID: 20844460619     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0085     Document Type: Article

References (20)

1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (Wash DC) 1998;279:577-80.
2. Koh JS, Trent JC, Chen LL, et al. Gastrointestinal stromal tumors: Overview of pathologic features, molecular biology, and therapy with imatinib mesylate. Histol Histopathol 2004;19:565-74.
3. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21: 4342-9.
4. Allander SV, Nupponen NN, Ringnér M, et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 2001;61:8624-8.
5. Sommer G, Agosti V, Ehlers I, et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA 2003;100:6706-11.
6. Ma Y, Cunningham ME, Wang X, Ghosh I, Regan L, Longley BJ. Inhibition of spontaneous receptor phosphorylation by residues in a putative α-helix in the KIT intracellular juxtamembrane region. J Biol Chem 1999;274:13399-402.
7. Chan PM, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R. Autoinhibition of the Kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol 2003;23:3067-78.
8. Kinoshita K, Isozaki K, Hirota S, et al. C-kit Gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol 2003;18: 147-51.
9. Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of kit gene. Gastroenterology 2002;122:1493-99.
10. Heinrich MC, Corless CL, Deunsing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science (Wash DC) 2003;299:708-10.
11. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor a gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-7.
12. Fabbro D, Ruetz S, Buchdunger E, et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 2002;93:79-98.
13. Manley PW, Cowan-Jacob SW, Buchdunger E, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 2002;38:S19-27.
14. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
15. Kitamura Y, Hirota S, Nishida T. Gastrointestinal stromal tumors (GIST): A model for molecule-based diagnosis and treatment of solid tumors. Cancer Sci 2003;94: 315-20.
16. Crosier PS, Ricciardi ST, Hall LR, Vitas MR, Clark SC, Crosier KE. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood 1993;82:1151-8.
17. Mol CD, Lim KB, Sridhar V, et al. Structure of c-kit product complex reveals the basis for kinase transactivation. J Biol Chem 2003;278:31461-4.
18. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-43.
19. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash DC) 2001;293:876-80.
20. Roche-Lestienne C, Soenen-Comu V, Grardel-Duflos N, et al. Several types of mutations of the Ab1 gene can be found in chronic myeloid leukemia patients resistant to ST1571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014-8.